The influence of folate pathway polymorphisms on high-dose methotrexate-related toxicity and survival in children with non-Hodgkin malignant lymphoma

  • Nina Erčulj Pharmacogenetics Laboratory, Institute of Biochemistry Faculty of Medicine, University of Ljubljana Vrazov trg 2 SI-1000 Ljubljana Slovenia
  • Barbara Faganel Kotnik Department of Hematology and Oncology, University Children's Hospital, University Medical Centre, Bohoričeva 20, 1000 Ljubljana, Slovenia
  • Maruša Debeljak Centre for Medical Genetics, University Children's Hospital, University Medical Centre, Vrazov trg 1, 1000 Ljubljana, Slovenia
  • Janez Jazbec Department of Hematology and Oncology, University Children's Hospital, University Medical Centre, Bohoričeva 20, 1000 Ljubljana, Slovenia
  • Vita Dolžan Pharmacogenetics Laboratory, Institute of Biochemistry Faculty of Medicine, University of Ljubljana Vrazov trg 2 SI-1000 Ljubljana Slovenia

Abstract

We evaluated the influence of folate pathway polymorphisms on high-dose methotrexate (HD-MTX) related toxicity in pediatric patients with T-cell non-Hodgkin lymphoma (NHL). In total, 30 NHL patients were genotyped for selected folate pathway polymorphisms. Carriers of at least one MTHFR 677T allele had significantly higher MTX area under the time-concentration curve levels at third MTX cycle (P=0.003). These patients were also at higher odds of leukopenia (P=0.006) or thrombocytopenia (P=0.041) and had higher number of different HD-MTX-related toxicity (P=0.035) compared to patients with wild-type genotype. Our results suggest an important role of MTHFR 677C>T polymorphism in the development of HD-MTX-related toxicity in children with NHL.

Published
2014-08-27
How to Cite
Erčulj, N., Faganel Kotnik, B., Debeljak, M., Jazbec, J., & Dolžan, V. (2014). The influence of folate pathway polymorphisms on high-dose methotrexate-related toxicity and survival in children with non-Hodgkin malignant lymphoma. Radiology and Oncology, 48(3). Retrieved from https://radioloncol.com/index.php/ro/article/view/2004
Section
Clinical oncology